Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04432207 · ClinicalTrials.gov registry record · Phase 1
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Imugene Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04432207 is a Phase 1 study that was terminated before completion, run by Imugene Limited. The registered enrollment target is 24 participants.
The verdict
NCT04432207, a Phase 1 study, was terminated before completion, sponsored by Imugene Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU 201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell Lung Cancer (IMPrinter).
Interventions
- DRUG Atezolizumab
- BIOLOGICAL IMU-201 (administered as PD1-Vaxx) - Regimen 1
- BIOLOGICAL IMU-201 (administered as PD1-Vaxx) - Regimen 2
- BIOLOGICAL IMU-201 (administered as PD1-Vaxx) - Regimen 3
- DRUG Standard of care chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04432207
The ClinicalTrials.gov registry entry for NCT04432207 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Imugene Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Atezolizumab is the first listed.
NCT04432207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04432207 about?
NCT04432207 is a clinical study titled "A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer". An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU 201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell Lung Cancer (IMPrinter).
What is the current status of trial NCT04432207?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-11-30. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT04432207?
The interventions under investigation include: Atezolizumab (DRUG), IMU-201 (administered as PD1-Vaxx) - Regimen 1 (BIOLOGICAL), IMU-201 (administered as PD1-Vaxx) - Regimen 2 (BIOLOGICAL), IMU-201 (administered as PD1-Vaxx) - Regimen 3 (BIOLOGICAL), Standard of care chemotherapy (DRUG).
Who is sponsoring clinical trial NCT04432207?
This trial is sponsored by Imugene Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.